When worlds collide
Award-winning historian Martin Thomas tells how the US-Australian scientific expedition team set out with fanfare in 1948 and how quickly the expedition turned toxic.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
9 News
14 hours ago
- 9 News
Wendy's cancer might be incurable, but she just wants to help future patients
Your web browser is no longer supported. To improve your experience update it here When Wendy Clift went for a routine breast scan in 2007, she got call from her doctors almost immediately. "The news wasn't good," the widowed grandmother of two from Scone in regional NSW told Wendy Clift was diagnosed with breast cancer in 2007. (Supplied) Just days later, she had a mastectomy, followed by more treatment. While it was successful in keeping her in remission for a few years, the cancer has now returned and it has spread. However, Clift, now 72, was invited to be part of a new Australian drug trial. It's hoped it could help patients with a certain kind of breast cancer live longer. The DIAmOND clinical trial showed adding dual immunotherapy to existing treatments could be promising for some patients with advanced HER2-positive breast cancer. Clift said her cancer appears to be "pretty stable" after the trial earlier this year, which she did at Lake Macquarie Private Hospital. Some of the cancerous lumps she had have even disappeared, though she doesn't know if that's due to the new drug combination. Clift said she didn't have side effects. She said taking part in the trial was less about her and more to help future patients. "I'm just prepared because whatever happens to me is neither here nor there, but hopefully in years to come it'll help somebody else," she said. Immunotherapy is a treatment that uses a person's immune system to treat certain cancers. Wendy Clift, pictured with son Joshua and grandchildren Florence and Arthur, says she just wants to help future cancer patients. (Supplied) The other drug used alongside this in the trial was trastuzumab, commonly known as Herceptin. The trial aimed to see if combining the two could prolong the amount of time cancer was under control in patients with advanced disease which had become resistant to trastuzumab. Results differed depending on the kind of cancer each of the 68 trial patients had. Some had a response rate of up to 63 per cent, while for other kinds it was 27 per cent. Some patients saw their cancer controlled for more than two years. The combination of drugs has been given previously to people with lung cancer. Professor Sherene Loi developed and led the trial, which was conducted by the research organisation Breast Cancer Trials. "These promising results suggest combining new immunotherapy treatments with trastuzumab may offer a new treatment option for patients with treatment-resistant HER2-positive breast cancer," Loi said. "These findings provide a compelling case for further exploration and how we can best integrate this treatment combination into clinical practice." HER2-positive breast cancer is a type of breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). However, it often responds well to specific treatments. Around 15-20 per cent of all types of breast cancers are HER2-positive. It is more common in younger, pre-menopausal women. cancer health drugs Australia medical national New South Wales CONTACT US Auto news:Is this the next Subaru WRX? Mysterious performance car teased.
AU Financial Review
a day ago
- AU Financial Review
Qld finally reveals its position on $1b quantum deal
Queensland's Liberal-National government confirmed it will proceed with the $1 billion deal to build a world-leading super computer following a months-long review and scathing comments of the agreement while in opposition. The Crisafulli government launched a review of the deal with US-based start-up PsiQuantum within days of coming to office in November, raising concerns about the decision-making and competitive rigour of the selection process.
Perth Now
a day ago
- Perth Now
‘Overwhelmed': Major virus breakthrough
Australian researchers have found a way to force the HIV virus out of hiding within cells, opening the way to eradicate the virus from the body. The human immunodeficiency virus is able to hide within white blood cells, presenting a serious roadblock for scientists pursuing a cure. Research from Melbourne's Peter Doherty Institute for Infection and Immunity, published in late-May, says work towards a cure is one step closer. The next hurdle is analysing whether revealing the virus allows the body's immune system to fight off the virus or if additional treatments need to be combined. Australian researchers are closer to a HIV cure. Credit: News Limited 'In terms of specifically the field of HIV cure, we have never seen anything close to as good as what we are seeing in terms of how well we are able to reveal this virus,' co-author Paula Cevaal told the Guardian. 'We were overwhelmed by how night-and-day difference it was – from not working before, and then all of a sudden it was working. And all of us were just sitting gasping like, 'Wow'.' The HIV that hides in white blood cells can reactivate. The Peter Doherty Institute researchers used custom-made fat bubbles to deliver mRNA into cells where HIV is hiding. The mRNA tells the cells to reveal the virus. Messenger RNA is a molecule that contains instructions for cells to make a protein. The technology rose to prominence during the Covid-19 pandemic. People with HIV have to take medication for their entire life to suppress the virus, avoid symptoms and to stop transmission to other people. About 30,000 Australians live with HIV. In 2023, 722 new cases were reported to health authorities. Globally, in 2023, an estimated 500,000 to 820,000 people died from HIV-related causes.
